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ABSTRACT
Monoacylglycerol lipase is a serine hydrolase that plays a major role in the degradation of the endocanna-
binoid neurotransmitter 2-arachidonoylglycerol. A wide number of MAGL inhibitors are reported in litera-
ture; however, many of them are characterised by an irreversible mechanism of action and this behavior
determines an unwanted chronic MAGL inactivation, which acquires a functional antagonism of the endo-
cannabinoid system. The possible use of reversible MAGL inhibitors has only recently been explored, due
to the lack of known compounds possessing efficient reversible inhibitory activities. In this work, we report
a new series of terphenyl-2-methyloxazol-5(4H)-one derivatives characterised by a reversible MAGL-inhib-
ition mechanism. Among them, compound 20b showed to be a potent MAGL reversible inhibitor
(IC50¼ 348nM) with a good MAGL/FAAH selectivity. Furthermore, this compound showed antiproliferative
activities against two different cancer cell lines that overexpress MAGL.
ARTICLE HISTORY
Received 28 July 2017
Revised 23 August 2017
Accepted 23 August 2017
KEYWORDS
Monoacylglycerol lipase
inhibitors; endocannabi-
noids; docking; molecular
dynamic simulations
Introduction
Endocannabinoids are lipid transmitters that act as endogenous
ligands of the CB1 and CB2 cannabinoid receptors. The endogen-
ous ligands 2-arachidonoylglycerol (2-AG) and N-arachidonoyl
ethanolamine (AEA) are considered as the two major endocannabi-
noids and modulate multiple physiological processes including
pain, inflammation, appetite, memory and emotion1. Their signal-
ing activity is terminated by enzymatic hydrolysis, which is mainly
mediated by serine hydrolase monoacylglicerol lipase (MAGL) and
fatty acid amide hydrolase (FAAH), respectively2. Because of its key
role in 2-AG catabolism, selective inactivation of MAGL represents
an interesting approach for obtaining the desirable effects of indir-
ect cannabinoid receptors activation. MAGL inhibition in the per-
iphery produces CB1-dependent antinociceptive effects in mouse
models of noxious chemical, inflammatory, thermal and neuro-
pathic pain3. Pharmacological and genetic blockades of MAGL
exhibit anti-inflammatory effects in the brain and neuroprotective
effects in mouse models of Parkinson’s and Alzheimer’s disease4.
Other studies suggest that MAGL inhibition produces anti-anxiety
responses5 and could be useful for modulating drug dependence
of opiates6. Finally, MAGL is upregulated in aggressive cancer cells
and primary tumors and its inhibition in aggressive breast, ovarian,
and melanoma cancer cells impairs cell migration, invasiveness,
and tumorigenicity7. Over the past 10 years, great efforts have
been done for identifying novel MAGL inhibitors8–13; however,
almost all the reported compounds are characterised by an irre-
versible MAGL-inhibition mechanism2. Among this wide class of
MAGL inhibitors, JZL18411 and CAY104998 (Figure 1) are the two
main compounds that are used as reference inhibitors for most of
the cellular and animal experiments in which MAGL is studied.
However, as reported by Scholsburg et al.14, the repeated adminis-
trations in mice of an irreversible MAGL inhibitor produces cross-
tolerance to CB1 agonists. Furthermore, chronic MAGL blockade
causes impaired endocannabinoid-dependent synaptic plasticity,
physical dependence and desensitised brain CB1 receptors
14.
Considering all these negative effects associated to the irreversible
MAGL inhibition, the need to discover selective and reversible
MAGL inhibitors constitutes a challenging opportunity to target
MAGL with minimal occurrence of unwanted side effects. To our
knowledge, only few compounds described as good reversible
MAGL inhibitors have so far been reported in literature. In 2014, a
reversible MAGL inhibitor (compound c21, Figure 1) was tested in
vivo using the EAE (experimental allergic encephalomyelitis)
mouse model and the ligand ameliorated the clinical progression
of the multiple sclerosis mouse model. Very importantly, the thera-
peutic effects were not accompanied by catalepsy or other motor
impairments which have been instead observed after the adminis-
tration of irreversible MAGL inhibitors15. Finally, in 2016, Tuccinardi
et al.16 reported a novel class of benzoylpiperidine derivatives as
potent and selective MAGL reversible inhibitors possessing anti-
proliferative activity against ovarian cancer cell lines (Figure 1,
compound 17b)17.
Very recently, the same authors developed a class of biphenyl
2-methyloxazol-5(4H)-one compounds of general structure A
(Figure 2) that inhibits MAGL reversibly and selectively.
Modeling studies revealed that the pharmacophoric portions are
both the 2-methyloxazol-5(4H)-one ring, interacting with the cata-
lytic S122 of the enzyme, and the peripheral phenyl ring, which
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nicely fits into a lipophilic cavity of the protein18. On the basis of
these results, and considering the wide available space within the
MAGL lipophilic cavity, we decided to add a second aromatic por-
tion, in order to adequately fill this region, while maintaining the
same central scaffold of the previous series of compounds (general
structure B, Figure 2). Therefore, we initially designed and synthes-
ised terphenyl-2-methyloxazol-5(4H)-one derivatives displaying all
the possible combinations of substitution positions on the central
phenyl ring by inserting unsubstituted phenyl rings. In a second
time, after a preliminary evaluation, the best obtained regioiso-
meric compound in terms of inhibitory enzymatic activity was
selected for further fine chemical modifications and, therefore,
variously substituted phenyl rings were introduced in the selected
positions to determine which kind of group was most suitable to
improve MAGL inhibitory potency and enzyme selectivity
properties.
Material and methods
Chemistry
Commercially available chemicals were purchased from Sigma-
Aldrich (St. Louis, MO, USA) or Alfa Aesar-Thermo Fisher Scientific
(Karlsruhe, Germany) and used without further purification. JZL-
184 and CAY10499 were purchased from Cayman Chemical. NMR
spectra were obtained with a Bruker Avance III 400MHz spectrom-
eter. Chemical shifts (d) are reported in parts per million downfield
from tetramethylsilane and referenced from solvent references.
HPLC analysis: all target compounds (i.e. assessed in biological
assays) were 94% pure by HPLC, confirmed via UV detection
(k¼ 310 nm). Analytical reversed-phase HPLC was conducted using
a Kinetex EVO C18 column (5mm, 150 4.6mm, Phenomenex,
Inc.); eluent A, water; eluent B, CH3CN; after 3min at 25% B, a gra-
dient was formed from 25 to 85% of B in 4min and held at 85%
of B for 8min; flow rate was 1ml/min. Chromatographic
separations were performed on silica gel columns by flash chroma-
tography (Kieselgel 60, 0.040–0.063mm; Merck). Reactions were
followed by thin-layer chromatography (TLC) on Aldrich aluminum
silica gel (F254) sheets that were visualised under a UV lamp.
Evaporation was performed in vacuo (rotating evaporator).
Sodium sulfate was always used as the drying agent. Elemental
analysis has been used to determine the purity of target com-
pounds. Analytical results are within ±0.40% of the theoretical
values.
General procedure for the formation of terphenyl derivatives 6,
12, 14 and 19a–h
A solution of Pd(OAc)2 (0.06 eq) and triphenylphosphine (0.30 eq)
in absolute ethanol (6ml/2.7mmol halogenated derivative) and
toluene (6ml/2.7mmol halogenated derivative) was stirred at
room temperature (RT) under nitrogen for 10min. After that
period, commercially available dibromo- or dichloro-substituted
aldehydes 2, 10 or 11 (1 eq), 2 M aqueous Na2CO3 (6ml/2.7mmol
halogenated derivative), and opportunely substituted phenylbor-
onic acid (3.2 eq) were sequentially added. The resulting mixture
was heated at 100 C in a sealed vial under nitrogen for 24 h. After
being cooled to RT, it was checked by TLC and if starting material
was still present or it was visible the presence of two close spots
(probable mono- and di-substitution products), it was added
Pd(OAc)2 (0.03 eq), triphenylphosphine (0.15 eq) and phenylbor-
onic acid (1.6 eq). The mixture was heated again at 100 C for fur-
ther 24 h. Finally, the mixture was cooled to RT, diluted with water
and extracted with EtOAc. The combined organic phase was dried
and concentrated. The crude product was purified by flash chro-
matography using the indicated eluent and pure fractions contain-
ing the desired compound were evaporated to dryness affording
the desired product.
(1,10:30,100-Terphenyl)-40-carbaldehyde (6)
Yellow crystalline solid, yield: 94% (277.4mg) from 2 and phenyl-
boronic acid. Rf¼ 0.11 (n-hexane/EtOAc 98:2). 1H-NMR (CDCl3,
400MHz) d (ppm): 7.39–7.53 (m, 8H), 7.65–7.70 (m, 3H), 7.73 (dd,
1H, J¼ 8.2, 1.0 Hz), 8.12 (d, 1H, J¼ 8.0 Hz), 10.02 (s, 1H).
(1,10:30,100-Terphenyl)-50-carbaldehyde (12)
White solid, yield: 93% (274.0mg) from 10 and phenylboronic
acid. Rf¼ 0.08 (n-hexane/EtOAc 98:2). 1H-NMR (CDCl3, 400MHz) d
(ppm): 7.43 (tt, 2H, J¼ 7.4, 1.7 Hz), 7.48–7.53 (m, 4H), 7.67–7.71 (m,
4H), 8.06–8.10 (m, 3H), 10.16 (s, 1H).
(1,10:40,100-Terphenyl)-20-carbaldehyde (14)
White solid, yield: 80% (236.0mg) from 11 and phenylboronic
acid. Rf¼ 0.17 (n-hexane/EtOAc 98:2). 1H-NMR (CDCl3, 400MHz) d
(ppm): 7.38–7.57 (m, 9H), 7.67–7.71 (m, 2H), 7.89 (dd, 1H, J¼ 8.0,
2.1 Hz), 8.28 (d, 1H, J¼ 2.0 Hz), 10.05 (s, 1H).
4,40 0-Difluoro-(1,10:40,10 0-terphenyl)-20-carbaldehyde (19a)
White solid, yield: 97% (325.5mg) from 11 and 4-fluorophenylbor-
onic acid. Rf¼ 0.18 (n-hexane/EtOAc 98:2). 1H-NMR (CDCl3,
400MHz) d (ppm): 7.14–7.22 (m, 4H), 7.39 (double AA0XX0, 2H, 4JHF-m
¼ 5.3 Hz, JAX¼ 8.8 Hz, JAA0/XX0 ¼ 2.5 Hz), 7.50 (d, 1H, J¼ 7.9 Hz),
7.64 (double AA0XX0, 2H, 4JHF-m¼ 5.2 Hz, JAX¼ 8.8 Hz,
JAA0/XX0 ¼ 2.6 Hz), 7.83 (dd, 1H, J¼ 8.0, 2.1 Hz), 8.20 (d, 1H,
J¼ 2.0 Hz), 10.02 (s, 1H).
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Figure 1. Structures of some of the most relevant MAGL inhibitors.
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Figure 2. Structural evolution of methyleneoxazol-5(4H)-one scaffold: previously
developed biphenyl 2-methyloxazol-5(4H)-one compounds (A) and newly synthes-
ised terphenyl-2-methyloxazol-5(4H)-one derivatives (B).
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4,400-Dimethoxy-(1,10:40,10 0-terphenyl)-20-carbaldehyde (19b)
White solid, yield: 99% (363.5mg) from 11 and 4-methoxyphenyl-
boronic acid. Rf¼ 0.25 (n-hexane/EtOAc 9:1). 1H-NMR (CDCl3,
400MHz) d (ppm): 3.87 (s, 3H), 3.89 (s, 3H), 6.99–7.05 (m, 4H), 7.35
(AA0XX0, 2H, JAX¼ 8.8 Hz, JAA0/XX0 ¼ 2.1 Hz), 7.49 (d, 1H, J¼ 8.0 Hz),
7.62 (AA0XX0, 2H, JAX¼ 8.9 Hz, JAA0/XX0 ¼ 2.2 Hz), 7.82 (dd, 1H, J¼ 8.0,
2.1 Hz), 8.20 (d, 1H, J¼ 2.0 Hz), 10.05 (s, 1H).
4,400-Bis(trifluoromethoxy)-(1,10:40,10 0-terphenyl)-20-carbaldehyde
(19c)
Colorless oil, yield: 89% (432.1mg) from 11 and 4-trifluoromethox-
yphenylboronic acid. Rf¼ 0.13 (n-hexane/EtOAc 99:1). 1H-NMR
(CDCl3, 400MHz) d (ppm): 7.32–7.38 (m, 4H), 7.46 (AA0XX0, 2H,
JAX¼ 8.8 Hz, JAA0/XX0 ¼ 2.4 Hz), 7.52 (d, 1H, J¼ 8.0 Hz), 7.69 (AA0XX0,
2H, JAX¼ 8.9 Hz, JAA0/XX0 ¼ 2.5 Hz), 7.86 (dd, 1H, J¼ 8.0, 2.2 Hz), 8.23
(d, 1H, J¼ 1.8 Hz), 10.03 (s, 1H).
4,400-Bis(trifluoromethyl)-(1,10:40,10 0-terphenyl)-20-carbaldehyde
(19d)
White solid, yield: 95% (424.8mg) from 11 and 4-trifluoromethyl-
phenylboronic acid. Rf¼ 0.15 (n-hexane/EtOAc 99:1). 1H-NMR
(CDCl3, 400MHz) d (ppm): 7.54–7.59 (m, 3H), 7.74–7.81 (m, 6H),
7.92 (dd, 1H, J¼ 8.0, 2.1 Hz), 8.30 (d, 1H, J¼ 1.8 Hz), 10.03 (s, 1H).
3,300-Difluoro-(1,10:40,10 0-terphenyl)-20-carbaldehyde (19e)
White solid, yield: 94% (316.0mg) from 11 and 3-fluorophenylbor-
onic acid. Rf¼ 0.10 (n-hexane/EtOAc 98:2). 1H-NMR (CDCl3,
400MHz) d (ppm): 7.07–7.14 (m, 1H), 7.14–7.21 (m, 3H), 7.35–7.40
(m, 1H), 7.42–7.50 (m, 3H), 7.53 (d, 1H, J¼ 8.0 Hz), 7.87 (dd, 1H,
J¼ 8.0, 2.1 Hz), 8.25 (d, 1H, J¼ 2.0 Hz), 10.04 (s, 1H).
2,5-Bis[benzo(d)(1,3)dioxol-5-yl]benzaldehyde (19f)
Dark yellow solid, yield: 75% (295.6mg) from 11 and 3,4-(methyle-
nedioxy)phenylboronic acid. Rf¼ 0.18 (n-hexane/EtOAc 9:1).
1H-NMR (CDCl3, 400MHz) d (ppm): 6.03 (s, 2H), 6.06 (s, 2H), 6.83
(dd, 1H, J¼ 7.8, 1.9 Hz), 6.89–6.94 (m, 3H), 7.12–7.16 (m, 2H), 7,47
(d, 1H, J¼ 8.0 Hz), 7,77 (dd, 1H, J¼ 8.0, 2.1 Hz), 8.15 (d, 1H,
J¼ 2.0 Hz), 10.05 (s, 1H).
3,300-Difluoro-4,40 0-dimethoxy-(1,10:40,100-terphenyl)-20-carbaldehyde
(19g)
Pearly white solid, yield: 82% (329.5mg) from 11 and 3-fluoro-4-
methoxyphenylboronic acid. Rf¼ 0.13 (n-hexane/EtOAc 9:1).
1H-NMR (CDCl3, 400MHz) d (ppm): 3.96 (s, 3H), 3.97 (s, 3H),
7.04–7.12 (m, 3H), 7.19 (dd, 1H, J¼ 11.6, 2.0 Hz), 7.38–7.44 (m, 2H),
7.48 (d, 1H, J¼ 8.0 Hz), 7.80 (dd, 1H, J¼ 8.0, 2.1 Hz), 8.18 (d, 1H,
J¼ 2.0 Hz), 10.05 (s, 1H).
4,400-Dichloro-(1,10:40,10 0-terphenyl)-20-carbaldehyde (19h)
White solid, yield: 61% (143.0mg) from 11 and 4-chlorophenylbor-
onic acid. Rf¼ 0.40 (n-hexane/EtOAc 98:2). 1H-NMR (CDCl3,
400MHz) d (ppm): 7.36 (AA0XX0, 2H, JAX¼ 8.6 Hz, JAA0/XX0 ¼ 2.3 Hz),
7.44–7.52 (m, 5H), 7.61 (AA0XX0, 2H, JAX¼ 8.7 Hz, JAA0/XX0 ¼ 2.3 Hz),
7.85 (dd, 1H, J¼ 8.0, 2.1 Hz), 8.22 (d, 1H, J¼ 2.1 Hz), 10.03 (s, 1H).
Procedure for the synthesis of (1,10:20,10 0-terphenyl)-40-carbalde-
hyde (4)
3,4-Dichlorobenzaldehyde 1 (500mg, 2.86mmol, 1 eq) was placed
in a vial together with phenylboronic acid (1.39 g, 11.4mmol),
potassium phosphate (2.67 g, 12.6mmol), Pd(OAc)2 (57.8mg,
0.0858mmol), tetrabutylammonium bromide (TBAB) (14.3 g,
44.3mmol) and water (6.4ml). The vial was sealed and heated under
stirring at 125 C for 48 h. The reaction mixture was cooled to RT
and then diluted with water. The water phase was acidified with 1 N
aqueous HCl and repeatedly extracted with EtOAc. The combined
organic phase was washed with brine, dried over anhydrous sodium
sulfate and evaporated to afford a crude residue that was purified
by column chromatography over silica gel using n-hexane/EtOAc
98:2 (Rf¼ 0.16) as the eluent, to give pure 4 as a yellow oily com-
pound (157.9mg, 21% yield). 1H-NMR (DMSO-d6, 400MHz) d (ppm):
7.14–7.20 (m, 4H), 7.25–7.32 (m, 6H), 7,65 (d, 1H, J¼ 8.0 Hz), 7.94
(d, 1H, J¼ 1.2 Hz), 7.98 (dd, 1H, J¼ 7.6, 1.6 Hz), 10.11 (s, 1H).
Procedure for the synthesis of (1,10:20,10 0-terphenyl)-30-carbalde-
hyde (8)
A solution of Pd(OAc)2 (0.06 eq) and triphenylphosphine (0.30 eq) in
absolute ethanol (6ml/2.7mmol halogenated derivative) and tolu-
ene (6ml/2.7mmol halogenated derivative) was stirred at RT under
nitrogen for 10min. After that period, commercially available 2,3-
dichlorobenzaldehyde 3 (300mg, 1.71mmol, 1 eq), 2 M aqueous
Na2CO3 (6ml/2.7mmol halogenated derivative), and phenylboronic
acid (3.2 eq) were sequentially added. The resulting mixture was
heated at 100 C in a sealed vial under nitrogen for 24 h. After being
cooled to RT, the mixture was diluted with water and extracted with
EtOAc. The combined organic phase was dried and concentrated.
Since 1H-NMR analysis revealed the formation of a mono-substitu-
tion product, the crude (320mg) was dissolved in anhydrous
dioxane (3.7ml) and treated, under nitrogen, with cesium carbonate
(1.7 eq), phenylboronic acid (1.6 eq), Pd2(dba)3 (0.032 eq), and a
20% solution of tricyclohexylphosphine in toluene (0.08 eq). The
reaction was heated at 100 C in a sealed vial overnight. The reac-
tion mixture was then cooled to RT, diluted with EtOAc, and filtered
through a Celite pad. The organic filtrate was concentrated under
vacuum, and the crude product was purified by flash chromatog-
raphy (n-hexane/EtOAc 99:1, Rf¼ 0.08) to yield pure 8 as a white
solid (244.3mg, 55% total yield over two steps). 1H-NMR (CDCl3,
400MHz) d (ppm): 7.03–7.07 (m, 2H), 7.08–7.13 (m, 2H), 7.15–7.20
(m, 3H), 7.23–7.29 (m, 3H), 7.56 (t, 1H, J¼ 7.7 Hz), 7.65 (dd, 1H,
J¼ 7.6, 1.5 Hz), 8.04 (dd, 1H, J¼ 7.8, 1.5 Hz), 9.81 (s, 1H).
Procedure for the synthesis of (1,10:30,10 0-terphenyl)-20-carbalde-
hyde (17)
2,6-Dichlorobenzaldehyde 16 (500mg, 2.86mmol, 1 eq) was dis-
solved in anhydrous dioxane (7.2ml) and treated, under nitrogen,
with cesium carbonate (3.4 eq), phenylboronic acid (3.2 eq),
Pd2(dba)3 (0.064 eq), and a 20% solution of tricyclohexylphosphine
in toluene (0.16 eq). The reaction was heated at 100 C in a sealed
vial overnight. After being cooled to RT, it was added Pd2(dba)3
(0.032 eq), tricyclohexylphosphine (0.08 eq) and phenylboronic acid
(1.6 eq). The mixture was heated again at 100 C for further 24 h.
The reaction mixture was then cooled to RT, diluted with EtOAc, and
filtered through a Celite pad. The organic filtrate was concentrated
under vacuum, and the crude product was purified by flash chroma-
tography (n-hexane/EtOAc 98:2, Rf¼ 0.13) to yield pure 17 as a crys-
talline yellow solid (685mg, 93% yield). 1H-NMR (CDCl3, 400MHz) d
(ppm): 7.33–7.47 (m, 12H), 7.60 (dd, 1H, J¼ 7.9, 7.4 Hz), 9.96 (s, 1H).
General procedure for the preparation of the 2-methyloxazol-
5(4H)-one derivatives 5, 7, 9, 13, 15
A mixture of diphenyl-substituted benzaldehydes 4, 6, 8, 12 or 14
(1 eq), N-acetylglycine (1 eq) and sodium acetate (1 eq) in acetic
1242 C. GRANCHI ET AL.
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anhydride (5ml/5mmol aldehyde) was stirred at reflux for 5 h and
then warmed to RT. The reaction was quenched with water and
extracted with AcOEt. The organic layer was washed sequentially
with water and saturated brine, dried over Na2SO4 and the solvent
was removed under reduced pressure. The residue was purified
with a flash column chromatography using the indicated eluent
and pure fractions containing the desired compound were evapo-
rated to dryness affording the desired product.
(Z)-4-[(1,10:20,10 0-Terphenyl)-40-ylmethylene]-2-methyloxazol-5(4H)-
one (5)
Yellow solid, yield: 23% (44.4mg) from 4. Rf¼ 0.21 (n-hexane/
EtOAc 95:5). 1H-NMR (CDCl3, 400MHz) d (ppm): 2.41 (s, 3H),
7.12–7.18 (m, 4H), 7.20–7.27 (m, 7H), 7.52 (d, 1H, J¼ 8.0 Hz), 8.07
(d, 1H, J¼ 1.8 Hz), 8.19 (dd, 1H, J¼ 8.2, 1.7 Hz). 13C-NMR (CDCl3,
100MHz) d (ppm): 15.86, 127.01, 127.22, 128.16 (2 C), 128.19 (2 C),
129.86 (2 C), 129.99 (2 C), 131.09, 131.14, 131.36, 132.54, 132.96,
134.56, 140.75, 140.86, 141.34, 143.50, 166.29, 167.98. HPLC ana-
lysis: retention time¼ 11.207min; peak area, 95%. Elemental ana-
lysis for C23H17NO2 calculated: % C, 81.40; % H, 5.05; % N, 4.13;
found: % C, 81.10; % H, 5.03; % N, 4.12.
(Z)-4-[(1,10:30,10 0-Terphenyl)-40-ylmethylene]-2-methyloxazol-5(4H)-
one (7)
Yellow solid, yield: 11% (55.2mg) from 6. Rf¼ 0.13 (n-hexane/
EtOAc 95:5). 1H-NMR (CDCl3, 400MHz) d (ppm): 2.43 (s, 3H), 7.24
(s, 1H), 7.35–7.50 (m, 8H), 7.63–7.69 (m, 3H), 7.72 (dd, 1H, J¼ 8.3,
1.9 Hz), 8.79 (d, 1H, J¼ 8.3 Hz). 13C-NMR (CDCl3, 100MHz) d (ppm):
15.89, 126.48, 127.29, 127.35, 128.19, 128.30, 128.62, 128.69 (2 C),
129.05, 129.11 (2 C), 129.15, 130.06, 130.09, 132.70, 132.71, 139.95,
140.09, 143.40, 145.72, 166.25, 167.75. HPLC analysis: retention
time¼ 11.349min; peak area, 96%. Elemental analysis for
C23H17NO2 calculated: % C, 81.40; % H, 5.05; % N, 4.13; found: %
C, 81.32; % H, 5.04; % N, 4.12.
(Z)-4-[(1,10:20,10 0-Terphenyl)-30-ylmethylene]-2-methyloxazol-5(4H)-
one (9)
Yellow solid, yield: 13% (39.4mg) from 8. Rf¼ 0.14 (n-hexane/
EtOAc 95:5). 1H-NMR (CDCl3, 400MHz) d (ppm): 2.41 (s, 3H),
6.90–7.05 (m, 5H), 7.12–7.17 (m, 3H), 7.20–7.25 (m, 3H), 7.48 (dd,
1H, J¼ 7.6, 1.5 Hz), 7.54 (t, 1H, J¼ 7.7 Hz), 8.65 (dd, 1H, J¼ 7.8,
1.4 Hz). 13C-NMR (CDCl3, 100MHz) d (ppm): 15.86, 126.64, 127.57,
127.81 (3 C), 128.01 (2 C), 129.82 (2 C), 130.97, 131.03, 131.29
(2 C), 132.23, 132.74, 132.87, 138.12, 141.21, 142.40, 143.29, 166.41,
167.56. HPLC analysis: retention time¼ 10.983min; peak area, 94%.
Elemental analysis for C23H17NO2 calculated: % C, 81.40; % H, 5.05;
% N, 4.13; found: % C, 81.07; % H, 5.03; % N, 4.11.
(Z)-4-[(1,10:30,10 0-Terphenyl)-50-ylmethylene]-2-methyloxazol-5(4H)-
one (13)
Yellow solid, yield: 41% (142.0mg) from 12. Rf¼ 0.17 (n-hexane/
EtOAc 95:5). 1H-NMR (CDCl3, 400MHz) d (ppm): 2.43 (s, 3H), 7.27
(s, 1H), 7.41 (tt, 2H, J¼ 7.3, 1.5 Hz), 7.47–7.53 (m, 4H), 7.66–7.70 (m,
4H), 7.86 (t, 1H, J¼ 1.7 Hz), 8.30 (d, 2H, J¼ 1.6 Hz). 13C-NMR
(CDCl3, 100MHz) d (ppm): 15.73, 128.06, 128.76, 128.84, 129.89
(11 C), 130.36, 130.58, 134.59, 135.60, 141.13, 143.16, 168.14,
168.21. HPLC analysis: retention time¼ 11.496min; peak area, 97%.
Elemental analysis for C23H17NO2 calculated: % C, 81.40; % H, 5.05;
% N, 4.13; found: % C, 81.68; % H, 5.06; % N, 4.14.
(Z)-4-[(1,10:40,100-Terphenyl)-20-ylmethylene]-2-methyloxazol-5(4H)-
one (15)
Yellow solid, yield: 15% (43.0mg) from 14. Rf¼ 0.18 (n-hexane/
EtOAc 95:5). 1H-NMR (CDCl3, 400MHz) d (ppm): 2.42 (s, 3H), 7.11
(s, 1H), 7.41–7.57 (m, 9H), 7.75–7.79 (m, 2H), 7.84 (dd, 1H, J¼ 8.0,
2.0 Hz), 9.10 (d, 1H, J¼ 2.0 Hz). 13C-NMR (CDCl3, 100MHz) d (ppm):
15.74, 127.82 (3 C), 128.67, 128.70, 128.86, 129.44 (2 C), 129.92,
129.97 (2 C), 130.80 (2 C), 131.16, 131.80, 132.19, 134.52, 140.52,
141.24, 144.54, 168.16, 168.23. HPLC analysis: retention time-
¼ 11.425min; peak area, 95%. Elemental analysis for C23H17NO2
calculated: % C, 81.40; % H, 5.05; % N, 4.13; found: % C, 81.65; %
H, 5.06; % N, 4.15.
General procedure for the preparation of the 2-methyloxazol-
5(4H)-one derivatives 20a–h
The procedure for the synthesis of these compounds is similar to
that used for previous analog final products, with the exception of
the used equivalents of N-acetylglycine (2 eq) and sodium acetate
(2 eq).
(Z)-4-{[4,400-Difluoro-(1,10:40,10 0-terphenyl)-20-yl]methylene}-2-meth-
yloxazol-5(4H)-one (20a)
Yellow solid, yield: 35% (46.5mg) from 19a. Rf¼ 0.20 (n-hexane/
EtOAc 95:5). 1H-NMR (acetone-d6, 400MHz) d (ppm): 2.43 (s, 3H),
7.06 (s, 1H), 7.28–7.34 (m, 4H), 7.48 (double AA0XX0, 2H, 4JHF-m
¼ 5.4 Hz, JAX¼ 8.9 Hz, JAA0/XX0 ¼ 2.2 Hz), 7.55 (d, 1H, J¼ 8.0 Hz),
7.78–7.84 (m, 3H), 9.04 (d, 1H, J¼ 1.9 Hz). 13C-NMR (acetone-d6,
100MHz) d (ppm): 15.71, 116.25 (d, 2 C, J¼ 21.4 Hz), 116.69 (d,
2 C, J¼ 21.8 Hz), 128.23, 129.75 (d, 2 C, J¼ 8.1 Hz), 129.81, 131.03,
131.86, 132.32, 132.74 (d, 2 C, J¼ 8.1 Hz), 134.75, 136.68 (d,
J¼ 3.5 Hz), 137.27 (d, J¼ 3.2 Hz), 140.29, 143.29, 163.60 (d,
J¼ 234.1Hz),163.60 (d, J¼ 257.3Hz), 168.07, 168.42. HPLC analysis:
retention time¼ 11.375min; peak area, 96%. Elemental analysis for
C23H15F2NO2 calculated: % C, 73.59; % H, 4.03; % N, 3.73; found: %
C, 73.35; % H, 4.01; % N, 3.72.
(Z)-4-{[4,400-Dimethoxy-(1,10:40,10 0-terphenyl)-20-yl]methylene}-2-
methyloxazol-5(4H)-one (20b)
Yellow solid, yield: 19% (23.8mg) from 19b. Rf¼ 0.15 (n-hexane/
EtOAc 9:1). 1H-NMR (acetone-d6, 400MHz) d (ppm): 2.42 (s, 3H),
3.88 (s, 3H), 3.89 (s, 3H), 7.06–7.11 (m, 4H), 7.14 (s, 1H), 7.35
(AA0XX0, 2H, JAX¼ 8.8 Hz, JAA0/XX0 ¼ 2.6 Hz), 7.49 (d, 1H, J¼ 7.8 Hz),
7.70 (AA0XX0,2H, JAX¼ 8.9 Hz, JAA0/XX0 ¼ 2.6 Hz), 7.77 (dd, 1H, J¼ 8.1,
2.1 Hz), 9.03 (d, 1H, J¼ 2.0 Hz). 13C-NMR (acetone-d6, 100MHz) d
(ppm): 15.71, 55.60, 55.65, 114.55 (2 C), 114.85, 115.27 (2 C),
115.36, 128.67 (2 C), 128.82, 129.46, 130.62, 131.70, 131.84 (2 C),
131.99, 132.10, 139.79, 140.48, 160.38, 160.51, 166.44, 168.25. HPLC
analysis: retention time¼ 11.155min; peak area, 95%. Elemental
analysis for C25H21NO4 calculated: % C, 75.17; % H, 5.30; % N, 3.51;
found: % C, 74.90; % H, 5.28; % N, 3.50.
(Z)-4-{[4,400-Bis(trifluoromethoxy)-(1,10:40,10 0-terphenyl)-20-yl]methy-
lene}-2-methyloxazol-5(4H)-one (20c)
Yellow solid, yield: 32% (161.3mg) from 19c. Rf¼ 0.08 (n-hexane/
EtOAc 98:2). 1H-NMR (acetone-d6, 400MHz) d (ppm): 2.43 (s, 3H),
7.06 (s, 1H), 7.48–7.53 (m, 4H), 7.57–7.62 (m, 3H), 7.86–7.90
(m, 1H), 7.91 (AA0XX0, 2H, JAX¼ 8.6 Hz, JAA0/XX0 ¼ 1.9 Hz), 9.09 (d, 1H,
J¼ 1.8 Hz). 13C-NMR (acetone-d6, 100MHz) d (ppm): 15.74, 121.54
(q, 2 C, J¼ 256.0 Hz), 121.94, 122.51, 127.87, 129.64 (2 C), 129.97
(2 C), 131.29, 131.99 (2 C), 132.42, 132.64 (2 C), 135.07, 139.52,
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140.04, 140.15, 143.19, 149.83, 149.84, 168.00, 168.66. HPLC ana-
lysis: retention time¼ 13.106min; peak area, 94%. Elemental ana-
lysis for C25H15F6NO4 calculated: % C, 59.18; % H, 2.98; % N, 2.76;
found: % C, 59.40; % H, 2.99; % N, 2.77.
(Z)-4-{[4,40 0-Bis(trifluoromethyl)-(1,10:40,100-terphenyl)-20-yl]methy-
lene}-2-methyloxazol-5(4H)-one (20d)
Yellow solid, yield: 54% (260.3mg) from 19d. Rf¼ 0.18 (n-hexane/
EtOAc 9:1). 1H-NMR (acetone-d6, 400MHz) d (ppm): 2.44 (s, 3H),
7.04 (s, 1H), 7.65 (d, 1H, J¼ 8.0 Hz), 7.68–7.73 (m, 2H), 7.87–7.93
(m, 4H), 7.96 (dd, 1H, J¼ 8.1, 2.0 Hz), 7.99–8.04 (m, 2H), 9.16 (d, 1H,
J¼ 2.0 Hz). 13C-NMR (acetone-d6, 100MHz) d (ppm): 15.75, 125.36
(q, J¼ 271.5 Hz), 125.45 (q, J¼ 271.2 Hz), 126.37 (q, 2 C, J¼ 3.7 Hz),
126.91 (q, 2 C, J¼ 3.9 Hz), 127.46, 128.60, 130.14, 130.27 (q,
J¼ 32.3 Hz), 130.48 (q, J¼ 32.3 Hz), 131.57 (2 C), 132.02, 132.51,
135.34, 140.33, 143.55, 144.41 (q, 2 C, J¼ 1.4 Hz), 144.70 (q, 2 C,
J¼ 1.4 Hz), 167.93, 168.87. HPLC analysis: retention time-
¼ 12.638min; peak area, 97%. Elemental analysis for C25H15F6NO2
calculated: % C, 63.16; % H, 3.18; % N, 2.95; found: % C, 63.38; %
H, 3.17; % N, 2.96.
(Z)-4-{[3,30 0-Difluoro-(1,10:40,10 0-terphenyl)-20-yl]methylene}-2-meth-
yloxazol-5(4H)-one (20e)
Yellow solid, yield: 45% (89.5mg) from 19e. Rf¼ 0.20 (n-hexane/
EtOAc 95:5). 1H-NMR (acetone-d6, 400MHz) d (ppm): 2.43 (s, 3H),
7.05 (s, 1H), 7.18–7.30 (m, 4H), 7.48–7.63 (m, 5H), 7.87 (dd, 1H,
J¼ 8.0, 2.0 Hz), 9.07 (d, 1H, J¼ 2.0 Hz). 13C-NMR (acetone-d6,
100MHz) d (ppm): 15.75, 114.48 (d, J¼ 22.8 Hz), 115.44 (d,
J¼ 21.3 Hz), 115.70 (d, J¼ 21.3 Hz), 117.47 (d, J¼ 22.0 Hz), 123.80
(d, J¼ 2.9 Hz), 126.95 (d, J¼ 2.9 Hz), 127.83, 129.90, 131.22, 131.35
(d, J¼ 8.1 Hz) 131.88 (d, J¼ 9.9 Hz), 132.34, 135.02, 140.22, 142.73
(d, J¼ 7.9 Hz), 143.29 (d, J¼ 7.3 Hz), 143.45, 143.47, 163.56
(d, J¼ 245.7 Hz), 164.21 (d, J¼ 244.3 Hz), 168.02, 168.63. HPLC ana-
lysis: retention time¼ 11.405min; peak area, 97%. Elemental ana-
lysis for C23H15F2NO2 calculated: % C, 73.59; % H, 4.03; % N, 3.73;
found: % C, 73.40; % H, 4.02; % N, 3.72.
(Z)-4–[2,5-Bis(benzo[d][1,3]dioxol-5-yl)benzylidene]-2-methyloxazol-
5(4H)-one (20f)
Yellow solid, yield: 11% (25.9mg) from 19f. Rf¼ 0.10 (n-hexane/
Et2O 9:1).
1H-NMR (acetone-d6, 400MHz) d (ppm): 2.42 (s, 3H), 6.09
(s, 2H), 6.11 (s, 2H), 6.86 (dd, 1H, J¼ 8.0, 1.8 Hz), 6.93 (d, 1H,
J¼ 1.6 Hz), 6.97–7.01 (m, 2H), 7.14 (s, 1H), 7.22–7.27 (m, 2H), 7.48
(d, 1H, J¼ 8.0 Hz), 7.74 (dd, 1H, J¼ 8.1, 2.1 Hz), 8.97 (d, 1H,
J¼ 2.0 Hz). 13C-NMR (acetone-d6, 100MHz) d (ppm): 15.73, 66.82,
66.93, 102.39, 102.49, 108.02, 109.04, 109.55, 110.91, 121.47,
124.64, 128.92, 129.63, 130.82, 131.71, 132.22, 134.31, 135.23,
140.74, 143.81, 148.61, 148.93, 149.48. 168.08, 168.22. HPLC ana-
lysis: retention time¼ 10.849min; peak area, 95%. Elemental ana-
lysis for C25H17NO6 calculated: % C, 70.25; % H, 4.01; % N, 3.28;
found: % C, 69.98; % H, 3.99; % N, 3.27.
(Z)-4-{[3,30 0-Difluoro-4,40 0-dimethoxy-(1,10:40,10 0-terphenyl)-20-
yl]methylene}-2-methyloxazol-5(4H)-one (20g)
Yellow solid, yield: 12% (49.2mg) from 19g. Rf¼ 0.13 (n-hexane/
EtOAc 85:15). 1H-NMR (acetone-d6, 400MHz) d (ppm): 2.43 (s, 3H),
3.97 (s, 3H), 3.98 (s, 3H), 7.11 (s, 1H), 7.17 (ddd, 1H, J¼ 8.4, 2.2,
1.2 Hz), 7.23 (dd, 1H, J¼ 12.1, 2.1 Hz), 7.28 (td, 2H, J¼ 8.7, 3.5 Hz),
7.50–7.57 (m, 3H), 7.80 (dd, 1H, J¼ 8.1, 2.1 Hz), 9.01 (d, 1H,
J¼ 2.0 Hz). 13C-NMR (acetone-d6, 100MHz) d (ppm): 15.75, 56.65,
56.69, 115.11 (d, J¼ 18.9 Hz), 115.20, 118.18 (d, J¼ 18.1 Hz), 123.76
(d, J¼ 3.0 Hz), 125.60, 127.18 (d, J¼ 3.4 Hz), 128.48. 129.47, 130.71,
131.82, 132.26, 133.13 (d, J¼ 6.6 Hz), 133.83 (d, J¼ 6.3 Hz), 134.68,
139.71, 142.83, 148.56 (d, J¼ 3.6 Hz), 148.67 (d, J¼ 3.2 Hz), 152.84
(d, J¼ 245.8Hz), 153.48 (d, J¼ 244.7Hz), 168.15, 168.32. HPLC ana-
lysis: retention time¼ 11.015min; peak area, 99%. Elemental ana-
lysis for C25H19F2NO4 calculated: % C, 68.96; % H, 4.40; % N, 3.22;
found: % C, 68.97; % H, 4.41; % N, 3.21.
(Z)-4-{[4,400-Dichloro-(1,10:40,10 0-terphenyl)-20-yl]methylene}-2-meth-
yloxazol-5(4H)-one (20h)
Yellow solid, yield: 7% (18.1mg) from 19h. Rf¼ 0.18 (n-hexane/
EtOAc 95:5). 1H-NMR (acetone-d6, 400MHz) d (ppm): 2.43 (s, 3H),
7.05 (s, 1H), 7.46 (AA0XX0, 2H, JAX¼ 8.7 Hz, JAA0/XX0 ¼ 2.3 Hz),
7.54–7.59 (m, 5H), 7.79 (AA0XX0, 2H, JAX¼ 8.8 Hz, JAA0/XX0 ¼ 2.4 Hz),
7.85 (dd, 1H, J¼ 8.1, 2.0 Hz), 9.06 (d, 1H, J¼ 2.0 Hz). 13C-NMR (acet-
one-d6, 100MHz) d (ppm): 15.73, 127.95, 129.45 (2 C), 129.54 (2 C),
129.80, 130.03 (2 C), 131.10, 131.83, 132.34, 132.43 (2 C), 134.42,
134.65, 134.95. 139.14. 139.61, 140.20, 143.32, 168.01, 168.57. HPLC
analysis: retention time¼ 12.830min; peak area, 95%. Elemental
analysis for C23H15Cl2NO2 calculated: % C, 67.66; % H, 3.70; % N,
3.43; found: % C, 67.90; % H, 3.71; % N, 3.44.
Biological evaluation
MAGL-inhibition assay
Human recombinant MAGL, and 4-nitrophenylacetate substrate
(4-NPA) were from Cayman Chemical. The IC50 values for com-
pounds were generated in 96-well microtiter plates. The MAGL reac-
tion was conducted at RT at a final volume of 200 mL in 10mM Tris
buffer, pH 7.2, containing 1mM EDTA. A total of 150 mL of 4-NPA
133.3 mM (final concentration¼ 100mM) was added to 10 mL of
DMSO containing the appropriate amount of compound. The reac-
tion was initiated by the addition of 40 mL of MAGL (11 ng/well) in
such a way that the assay was linear over 30min. The final concen-
tration of the analyzed compounds ranged for CAY10499 and JZL-
184 from 10 to 0.00001 mM and for the synthesised compounds
from 200 to 0.0128 mM. After the reaction had proceeded for 30min,
absorbance values were then measured by using a VictorX3
PerkinElmer instrument at 405 nm. Two reactions were also run: one
reaction containing no compounds and the second one containing
neither inhibitor nor enzyme. IC50 values were derived from experi-
mental data using the Sigmoidal dose–response fitting of GraphPad
Prism software as reported earlier16. To remove possible false posi-
tive results, for each compound concentration a blank analysis was
carried out, and the final absorbance results were obtained detract-
ing the absorbance produced by the presence of all the compo-
nents except MAGL in the same conditions.
MAGL preincubation assay
The MAGL reaction was conducted at RT at a final volume of
200 mL in 10mM Tris buffer, pH 7.2, containing 1mM EDTA. A total
of 150 mL of MAGL (11 ng/well) was added to 10 mL of DMSO con-
taining the appropriate amount of compound. After 0, 30, and
60min of incubation time the reaction was initiated by the add-
ition of 40 mL of 4-NPA 500 mM. The enzyme activity was then
measured according to the procedure described above.
MAGL dilution assay
The enzyme (880 ng in 75 mL of Tris buffer, pH 7.2) was incubated
during 60min at RT with 5 mL of compound 20b (concentration of
10 mM in the mixture) dissolved in DMSO. The MAGL-inhibitor
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mixture was then diluted 40-fold with the buffer. After 15min of
incubation, the reaction was initiated on a 160 mL aliquot by the
addition of 40 mL of 4-NPA 500 mM and the enzyme activity was
measured according to the procedure described above.
FAAH inhibition assay
The IC50 values for compounds were generated in 96-well micro-
titer plates. The FAAH reaction was conducted at RT at a final vol-
ume of 200 mL in 125mM Tris buffer, pH 9.0, containing 1mM
EDTA. A total of 150 mL of AMC arachidonoyl amide 13.3mM (final
concentration¼ 10 mM) was added to 10 mL of DMSO containing
the appropriate amount of compound. The reaction was initiated
by the addition of 40mL of FAAH (0.9 mg/well) in such a way that
the assay was linear over 30min. After the reaction had proceeded
for 30min, fluorescence values were then measured by using a
VictorX3 PerkinElmer instrument at an excitation wavelength of
340 nm and an emission of 460 nm. Two reactions were also run:
one reaction containing no compounds and the second one con-
taining neither inhibitor nor enzyme. IC50 values were derived
from experimental data using the Sigmoidal dose response fit-
ting of GraphPad Prism software as reported earlier19. To remove
possible false-positive results, for each compound concentration, a
blank analysis was carried out, and the final fluorescence results
were obtained detracting the fluorescence produced by the pres-
ence of all the components except FAAH in the same conditions.
Cell viability assay
COV318, OVCAR-3 (from ATCC) and hMSC (from AB Cell-Bio) were
maintained at 37 C in a humidified atmosphere containing 5% CO2
accordingly to the supplier. Normal (1.5 104) and tumor (5 102)
cells were plated in 96-well culture plates. The day after seeding,
vehicle or compounds were added at different concentrations to
the medium. Compound was added to the cell culture at a concen-
tration ranging from 200 to 0.02 mM. Cell viability was measured
after 96 h according to the supplier (Promega, G7571) with a Tecan
F200 instrument. IC50 values were calculated from logistical dose–r-
esponse curves. Averages were obtained from three independent
experiments, and error bars are standard deviations (n¼ 3).
Molecular modeling
Consensus docking studies
The ligand was built by means of Maestro20 and was then mini-
mised in a water environment (using the Generalised Born/surface
area model) by means of Macromodel21. It was minimised using
the conjugate gradient (CG), the MMFFs force field, and a dis-
tance-dependent dielectric constant of 1.0 until they reached a
convergence value of 0.05 kcal Å1 mol1. Nine different docking
procedures were applied and for each docking calculation only
the best scored pose was taken into account22. The ligand was
docked in the human MAGL (3JWE23 PDB code) and the human-
ised-rat FAAH (3LJ724 PDB code). The ligand was docked into the
two proteins by using the different docking procedures, then the
root mean square deviation (RMSD) of each of these docking
poses against the remaining docking results was evaluated by
using the rms_analysis software of the GOLD suite. The most
populated cluster was then considered and subjected to molecular
dynamic (MD) simulations.
AUTODOCK 4.2.3
AUTODOCK Tools utilities25 were used in order to identify the tor-
sion angles in the ligand, to add the solvent model and assign the
Gasteiger atomic charges to proteins and ligand. The regions of
interest used by AUTODOCK26 were defined by considering the
reference ligand as the central group of a grid box of 10 Å in the
x, y, and z directions. A grid spacing of 0.375 Å and a distance-
dependent function of the dielectric constant were used for the
energetic map calculations. By using the Lamarckian genetic algo-
rithm, the docked compounds were subjected to 20 runs of the
AUTODOCK search using 2,500,000 steps of energy evaluation and
the default values of the other parameters.
DOCK 6.7
The molecular surface of the binding site was calculated by means
of the MS program27, generating the Connolly surface with a
probe with a radius of 1.4 Å. The points of the surface and the
vectors normal to it were used by the Sphgen program in order
to build a set of spheres, with radii varying from 1.4 to 4.0 Å that
describe, from a stereoelectronic point of view, the negative image
of the site. Spheres within a radius of 10 Å from the reference lig-
and were used to represent the site. For each docking calculation,
DOCK 6.7 calculated 1000 orientations; of these, the best grid
scored was taken into consideration. The ligand charge was calcu-
lated using the AM1-BCC method, as implemented in the
MOLCHARGE program28.
FRED 3.0
FRED29 requires a set of input conformers for each ligand. The con-
formers were generated by OMEGA230–32. The following modifica-
tions to the default settings of OMEGA2 were applied: the energy
window was set at 50.0, the maximum number of output conform-
ers was set at 10,000, the time limit was set at 1200, and the RMSD
value below which two conformations were considered to be similar
was set at 0.3 Å33. The region of interest for the docking studies was
defined in such a manner that it contained all residues which stayed
within 10 Å from the ligand in the X-ray structures. FRED default
parameters were used setting the high dock_resolution.
GLIDE 5.0
The binding site was defined by a rectangular box of 10 Å in the
x, y, and z directions centered on the ligand. The option allowing
only the docking of ligands containing a defined range of atoms
was deactivated, whereas the GLIDE34 defaults were used for all
other parameters. Docking calculations were carried out using the
standard precision (SP) method.
GOLD 5.1
The region of interest for the docking studies was defined in such a
manner that it contained all residues which stayed within 10 Å from
the ligand in the X-ray structures; the “allow early termination” com-
mand was deactivated, while the possibility for the ligand to flip
ring corners was activated. For all other parameters, GOLD35 defaults
were used and the ligands were subjected to 30 genetic algorithm
runs. Three docking analyzes were carried out by using three fitness
functions implemented in GOLD, i.e. GoldScore (GS), ChemScore
(CS) and Astex Statistical Potential (ASP).
AUTODOCK VINA 1.1
The input files for the ligand and proteins originated from the
AUTODOCK Tools utilities for the AUTODOCK calculations were
also used for the AUTODOCK VINA36 calculations, including the
grid box dimensions. The exhaustiveness parameter was set to 10
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and the Energy_range to 1, whereas for all other parameters,
AUTODOCK VINA defaults were used.
PLANTS
This docking software uses Ant Colony Optimisation, a state-of-
the-art global optimisation algorithm to find minima of a scoring
function representing favorable complex structures37. ChemPLP
scoring function was employed to score protein–ligand interac-
tions as well as intra-ligands clash terms. Standard settings for all
parameters were used for the scoring function as well as the opti-
misation algorithm (search speed setting: “speed1”). The regions
of interest used by PLANTS37 were defined by considering the ref-
erence ligand as the central group of a grid box of 10 Å in the x,
y, and z directions.
MD simulations
All simulations were performed using AMBER, version 1438. MD
simulations were carried out using the ff14SB force field at 300 K.
The complex was placed in a rectangular parallelepiped water
box. An explicit solvent model for water, TIP3P, was used, and the
complexes were solvated with a 20 Å water cap. Chlorine or
Sodium ions and were added as counter ions to neutralise the sys-
tem. Prior to MD simulations, two steps of minimisation were car-
ried out using the same procedure described above. Particle mesh
Ewald (PME) electrostatics and periodic boundary conditions were
used in the simulation39. The MD trajectory was run using the
minimised structure as the starting conformation. The time step of
the simulations was 2.0 fs with a cutoff of 10 Å for the nonbonded
interaction, and SHAKE was employed to keep all bonds involving
hydrogen atoms rigid. Constant-volume periodic boundary MD
was carried out for 1.0 ns, during which the temperature was
raised from 0 to 300 K. Then, 50 ns of constant-pressure periodic
boundary MD was carried out at 300 K using the Langevin
thermostat to maintain constant the temperature of our system.
All the a-carbons of the protein were blocked with a harmonic
force constant of 10 kcal/mol Å2. General Amber force field (GAFF)
parameters were assigned to the ligand, while partial charges
were calculated using the AM1-BCC method as implemented in
the Antechamber suite of AMBER 14.
Binding energy evaluation
The evaluation of the binding energy associated to the two
ligand–protein complexes analyzed through MD simulations was
carried out using AMBER 14. The trajectories relative to the last
50 ns of each simulation were extracted and used for the calcula-
tion, for a total of 50 snapshots (at time intervals of 1 ns). Van der
Waals, electrostatic and internal interactions were calculated with
the SANDER module of AMBER 14, whereas polar energies were
calculated using both the Generalised Born and the
Poisson Boltzman methods with the MM-PBSA module of AMBER
14. Dielectric constants of 1 and 80 were used to represent the
gas and water phases, respectively, while the MOLSURF program
was employed to estimate the nonpolar energies. The entropic
term was considered as approximately constant in the comparison
of the ligand protein energetic interactions.
Results and discussion
Chemistry
The terphenyl compounds were synthesised following the same
synthetic strategy applied for the previous series of methyleneoxa-
zol-5(4H)-one derivatives, differing only for the first step, in which
a double cross-coupling reaction was necessary to replace both
the halogen atoms by two phenyl rings in each appropriate
dihalo-substituted precursor (Schemes 1 and 2). All the possible
combinations of substitutions with phenyl rings in the central aro-
matic scaffold were explored, with the exception of the 2,6-
diphenyl derivative (Scheme 3, see the following chapter for
N
O
O
CH3
CH3
CH3
CHO
R3
CHO
CHO
CHO
N
O
O
N
O
O
1-3
1: R1 = H, R2 = Cl, R3 = Cl;
2: R1 = Cl, R2 = H, R3 = Cl;
3: R1 = Cl, R2 = Cl, R3 = H.
4
6
8
5
7
9
a
a
a
b
b
b
R2
R1
Scheme 1. Reagents and conditions: (a) for compound 4: phenylboronic acid, Pd(OAc)2, K3PO4, TBAB, H2O, 125 C; for compound 6: phenylboronic acid, Pd(OAc)2,
PPh3, aq. 2 M Na2CO3, toluene, EtOH, 100 C; for compound 8: phenylboronic acid, Pd(OAc)2, PPh3, aq. 2 M Na2CO3, toluene, EtOH, 100 C, then phenylboronic acid,
Pd2(dba)3, Cs2CO3, Cy3P 20% toluene, dioxane, 100 C; (b) N-acetylglycine, Ac2O, CH3COONa, reflux.
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discussion). According to the availability in our laboratory of the
starting aldehydes, the coupling reactions were performed on
dichloro- or dibromo-substituted compounds and different condi-
tions were chosen on the basis of a preliminary prevision of the
reaction outcome, which was highly dependent on the precursor
structure. 3,4-Dichlorobenzaldehyde 1 was subjected to a Pd-cata-
lyzed cross-coupling reaction under phosphine-free conditions in
water, by using TBAB as the phase-transfer agent, in the presence
of potassium phosphate, upon prolonged thermal heating40, to
give the diaryl derivative 4. An Erlenmeyer–Pl€ochl condensation of
the substituted aromatic aldehyde 4 with N-acetylglycine and
sodium acetate in refluxing acetic anhydride gave the final prod-
uct 5 as the (Z)-isomer (Scheme 1). In the case of 2,4-dichloroben-
zaldehyde 2, the classical thermal Pd(PPh3)4-catalyzed Suzuki
a
a
10: R1 = H, R2 = Br, R3 = Br;
11: R1 = Br, R2 = H, R3 = Br.
CHO
10-11
R1
R2
R3
CHO
CHO
b
b
N
O
O
CH3
CH3
13
N
O
O
15
12
14
Scheme 2. Reagents and conditions: (a) phenylboronic acid, Pd(OAc)2, PPh3, aq. 2 M Na2CO3, toluene, EtOH, 100 C; (b) N-acetylglycine, Ac2O, CH3COONa, reflux.
a
CHO
16
Cl
CHO
Ph
b N
O
O
CH318
Ph
17
Cl Ph Ph
Scheme 3. Reagents and conditions: (a) phenylboronic acid, Pd2(dba)3, Cs2CO3, Cy3P 20% toluene, dioxane, 100 C; b) N-acetylglycine, Ac2O, CH3COONa, reflux.
a
CHO
11
Br
Br
CHO
b N
O
O
CH3
19a-h
R1
R2
R1
R2
R1
R2
R1
R2
a: R1 = F, R2 = H;
b: R1 = OMe, R2 = H;
c: R1 = OCF3, R2 = H;
d: R1 = CF3, R2 = H;
e: R1 = H, R2 = F;
f: R1, R2 = -OCH2O-;
g: R1 = OMe, R2 = F;
h: R1 = Cl, R2 = H.
a: R1 = F, R2 = H;
b: R1 = OMe, R2 = H;
c: R1 = OCF3, R2 = H;
d: R1 = CF3, R2 = H;
e: R1 = H, R2 = F;
f: R1, R2 = -OCH2O-;
g: R1 = OMe, R2 = F;
h: R1 = Cl, R2 = H.
20a-h
Scheme 4. Reagents and conditions: (a) variously substituted phenylboronic acid, Pd(OAc)2, PPh3, aq. 2 M Na2CO3, toluene, EtOH, 100 C; (b) N-acetylglycine, Ac2O,
CH3COONa, reflux.
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conditions gave the desired product 6. This may appear as a sur-
prising outcome, because the starting material is an aryl chloride
which generally is less reactive under these “mild” cross-coupling
conditions that are commonly suitable for aryl bromides41.
Nevertheless, the presence of the aldehyde group in para or
ortho-position to the chloro atoms makes this compound more
reactive toward the cross-coupling reaction (Scheme 1).
Differently, in the case of 2,3-dichlrobenzaldehyde 3 we failed to
perform the double cross-coupling by using simple Suzuki condi-
tions, since 1H-NMR analysis revealed the formation of only a
mono-substitution product, probably due to the steric hindrance
caused by the two chlorine atoms in adjacent positions to the
aldehyde group. Therefore, the crude product of the reaction was
subjected again to a second cycle of cross-coupling, adopting the
Fu-type conditions42, which consists in using the more reactive
catalytic system comprised of Pd2(dba)3, together with tricyclohex-
ylphosphine as the catalyst ligand and cesium carbonate as the
base (Scheme 1). Both compounds 6 and 8 were then transformed
into the corresponding methyloxazol-5(4H)-one derivatives 7 and
9 as seen before for the preparation of 5 (Scheme 1).
The synthesis of terphenyl-methyloxazol-5(4H)-one compounds
13 and 15 started from bromo-aryl precursors 10 and 11 and
cross-coupling, which were performed by adopting Suzuki condi-
tions, allowed the formation of the diphenyl-substituted intermedi-
ates 12 and 14 with good yields, respectively (Scheme 2).
Finally, we tried to obtain the last derivative of this series of
compounds, which derives from the combination of the two phe-
nyl rings in both of the ortho-positions to the oxazolone ring
(compound 18, Scheme 3), starting from the 2,6-dichlorobenzalde-
hyde 16. Unfortunately intermediate 17, which was obtained in
high yield from 16 by a Fu-type coupling, did not react under the
classical Erlenmeyer–Pl€ochl conditions, neither by increasing the
equivalents of the reagents (N-acetylglycine and acetic anhydride:
tw0 equivalents) or by extending the reaction time (24 or 48 h).
This problem could be ascribed to the steric hindrance of the
structure bearing two phenyl rings close to the aldehyde moiety,
which hampered the formation of the additional five-membered
cycle.
Considering the promising biological activity of compound 15
(see “Biological evaluation” section), which proved to be the most
potent hMAGL inhibitor among all the possible combinations of
terphenyl derivatives synthesised, a series of similar compounds
variously substituted on the two peripheral aromatic rings were
prepared, in order to investigate the effects of the additional sub-
stituents on the enzyme inhibition potency. All these compounds
were obtained following the same synthetic pathway adopted for
compound 15 (Scheme 2). 2,5-Dibromobenzaldehyde 11 was sub-
jected to a double cross-coupling reaction using the Suzuki condi-
tions with the appropriate boronic acid. Then, intermediates
19a–h were reacted with N-acetylglycine and sodium acetate in
Table 1. Experimental inhibition activity (IC50) on human MAGL and FAAH of the analyzed compounds.
N
O OH3C
Ar1Ar4
Ar3 Ar2
5-13
# Ar1 Ar2 Ar3 Ar4 MAGL IC50 (nM) FAAH IC50 (nM) MAGL/FAAH selectivity
5 H Ph Ph H 837 ± 18 2321 ± 51 3
7 Ph H Ph H 546 ± 20 18161 ± 904 33
9 Ph Ph H H 2558 ± 172 20055 ± 1438 8
13 H Ph H Ph 457 ± 10 14763 ± 1176 32
15 Ph H H Ph 320 ± 10 10860 ± 161 34
N
O OH3C
R1
R2
R1
R2
15, 20a-h
# R1 R2 MAGL IC50 (nM) FAAH IC50 (nM) MAGL/FAAH selectivity
20a F H 683 ± 50 27989 ± 1306 41
20b OCH3 H 348 ± 38 36118 ± 1123 104
20c OCF3 H 4194 ± 299 17728 ± 1198 4
20d CF3 H 6763 ± 1125 28992 ± 1157 4
20e H F 628 ± 32 11713 ± 895 19
20f –OCH2O– 673 ± 23 23712 ± 1348 35
20g OCH3 F 335 ± 2 22311 ± 1239 67
20h Cl H 476 ± 39 11487 ± 998 24
CAY10499 144 ± 4 14.7 ± 0.2 0.1
JZL-184 49.8 ± 4.2 3301 ± 205 66
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refluxing acetic anhydride to give the final compounds 20a–h
(Scheme 4).
Biological evaluation
The inhibitory effects of the newly synthesised compounds on
human isoforms of MAGL and FAAH are reported in Table 1,
together with those of reference inhibitors CAY10499 and JZL-
184.
Given the wide range of biological processes regulated by
hydrolases, new MAGL inhibitors with a very high level of specifi-
city should be required to minimise mechanism-based toxicities.
Dual FAAH/MAGL inhibitors promote cataleptic and drug depend-
ence behaviors in mice that are more reminiscent of direct CB1
agonists43, underscoring the importance of maintaining high levels
of selectivity to avoid simultaneous blockade of both FAAH and
MAGL44.
The series of diphenyl-substituted derivatives (5, 7, 9, 13, and
15) revealed that the presence of adjacent phenyl rings in the
central scaffold is not ideal, since compound 5 (3,4-diphenyl) and,
in particular, 9 (2,3-diphenyl), show the weakest potencies of this
initial class. The introduction of further space between the two
phenyl rings progressively improves the inhibition abilities of these
compounds. In fact, when these substituents are placed in respect-
ive meta-positions (7 and 13), we can observe a significant
improvement of the IC50 values obtained. This effect is further
enhanced when the two phenyl rings are placed in para-positions
to each other, since compound 15 (2,5-diphenyl) displays the
highest MAGL-inhibition potency (IC50¼ 320 nM) and MAGL/FAAH
selectivity (34-fold) of this initial miniseries.
Therefore, we decided to further decorate the phenyl substitu-
ents of 15, and extend the series of 2,5-diaryl-substituted methyle-
neoxazol-5(4H)-one derivatives (20a–h). The data reported in
Table 1 show that relatively large substituents in the para-posi-
tions, such as OCF3 (20c) and CF3 (20d), do not seem to fit nicely
in the enzyme active site since the MAGL-inhibitory activities asso-
ciated to these compounds are very poor (IC50 values of 4–6 mM).
The introduction of small halogens, such as fluorine (20a,e) or
chlorine (20h) atoms, or of a dioxolane portion (20f) is better tol-
erated, although the IC50 values obtained with these compounds
are always higher than that of 15. Instead, the introduction of
para-methoxy groups in the peripheral aryl rings, although they
do not significantly improve the MAGL-inhibition potency of the
resulting compounds (20b, g) when compared to their unsubsti-
tuted counterpart 15, cause remarkable reductions of their FAAH-
inhibitory abilities, thus resulting in a substantial increase in their
MAGL/FAAH selectivity. This is particularly evident in 20b: this
compound displays an IC50 values of 348 nM against MAGL (similar
to that of 15), together with a noticeable 104-fold selectivity for
MAGL over FAAH, which is substantially higher than that shown
by both its unsubstituted analog 15 and by reference inhibitor
JZL-184. Comparing these results with those previously obtained
for the monophenyl-substituted derivatives, we can highlight an
improvement in terms of MAGL activity and MAGL/FAAH selectiv-
ity. In fact, the previously reported compounds showed a MAGL
activity in the low micromolar range (IC50¼ 1.0–2.2 mM) and a
MAGL/FAAH selectivity from 15 up to 69-fold18. Conversely, the
most active compounds of this series (15, 20b, 20g) displayed IC50
values ranging from 320 to 348 nM, thus the presence of two phe-
nyl rings placed in para-positions to each other markedly
increased the inhibitory potency on MAGL. Moreover, the presence
of a methoxy group in para-position on both phenyl rings allowed
an increase in the MAGL/FAAH selectivity up to 104-fold, as for
compound 20b. Therefore, this compound can be considered as
the most promising inhibitor of the present series of methyleneox-
azol-5(4H)-one derivatives.
In order to study the inhibition mechanism of the new
reported compounds, the effects of preincubation and dilution in
the inhibitory ability of compound 20b were evaluated. In the pre-
incubation experiments, an irreversible inhibitor will increase its
capacity to block the enzyme with increasingly longer incubation
times in the presence of enzyme prior to addition of substrate; a
constant IC50, conversely, supports a reversible mechanism
45. As
expected, compound 20b did not show any significant increase in
its ability to block MAGL activity after 30 and 60min (Figure 3(A)),
supporting that it should be a reversible inhibitor. In the dilution
experiments, if 20b is an irreversible inhibitor, then its inhibition
potency should not drop upon dilution, whereas inhibition levels
should be substantially reduced upon dilution in presence of a
reversible compound. As shown in Figure 3(B), 20b showed revers-
ible inhibition, since the inhibition produced by 10 mM of the
compound is significantly higher compared with the inhibition
observed upon 40 dilution, which appears similar to that pro-
duced by a 0.25 mM concentration of the compound.
Figure 3. Compound 20b-MAGL inhibition analysis. (A) IC50 (mM) values of 20b
at different preincubation times with hMAGL (0, 30 and 60min). (B) Dilution
assay: the first two columns indicate the inhibition percentage of compound 20b
at a concentration of 10 and 0.25 mM. The third column indicates the inhibition
percentage of compound 20b after dilution (final concentration ¼ 0.25 mM).
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Compounds 20b was also selected for in vitro experiments to
evaluate its antiproliferative potency on cancer cells. Two human
ovarian cancer cell lines, OVCAR3 and CAOV3, were chosen
because western blot analysis highlighted an overexpression of
MAGL in these two cell lines17. The compound produced appre-
ciable inhibition of cell viability for both cell lines, with IC50 values
of 41.6 mM for OVCAR3 and 23.8 mM for CAOV3. Furthermore, it
showed negligible potency against noncancerous human mesen-
chymal stem cells (hMSC, IC50>100 mM).
Molecular modeling studies
To suggest a possible binding mode for this class of derivatives,
the interaction of compound 20b with MAGL and FAAH was ana-
lyzed by means of docking and MD simulations. This docking ana-
lysis helps us to identify the most significant interactions of the
compound before the formation of the covalent bond with the
catalytic serine, thus highlighting the key points for the ligand rec-
ognition. As a first step, a consensus docking method was applied
as it is shown to predict the ligand-binding pose better than the
single docking programs46. By using this kind of approach, one lig-
and is docked into the target protein by means of different dock-
ing procedures. Then, among the different best-ranked poses
(originated by the different docking procedures) the pose in com-
mon with the largest number of docking procedures is considered
as the best docking pose. The 20b-MAGL and 20b-FAAH com-
plexes obtained by means of this docking strategy were then sub-
jected to 51 ns of MD simulation with explicit water molecules, as
described in the “Material and methods” section. Figure 4(A)
shows the main interactions of 20b with MAGL. The dimethoxyter-
phenyl fragment occupies the central core of the binding site
showing a large number of lipophilic interactions such as those
with L148, A151, P178, I179, L184, L205, L213 and L241; whereas
the 2-methyloxazolone ring is placed near the catalytic S122 and
forms two H-bonds with the nitrogen backbone of A51 (HB1,
Figure 4(A)) and M123 (HB2, Figure 4(A)). Interestingly, as shown
in Figure 4(B) the H-bonds interactions between the ligand and
A51 and M123 displayed a high stability, as they were maintained
for the whole MD simulation.
As shown in Figure 5, the binding site shape of FAAH does not
seem to allow an interaction of the 2-methyloxazolone ring of
20b in proximity to the catalytic region of the enzyme. The ligand
shows a binding disposition that is completely different from that
observed in the MAGL binding site, and the 2-methyloxazolone
ring is 10 Å away from the catalytic S241. Furthermore, the com-
pound does not form any H-bonds with the protein and the lig-
and is stabilised only by lipophilic interactions with F192, I238,
L380, L404 and F432.
In order to further analyze the interaction of 20b into MAGL
and FAAH, the two MD trajectories were further analyzed through
the MM–PBSA method47, which has shown to accurately estimate
the ligand–protein energy interaction48–50. This approach averages
contributions of gas-phase energies, solvation free energies, and
solute entropies calculated for snapshots of the complex molecule
as well as the unbound components extracted from MD trajecto-
ries, according to the procedure fully described in “Material and
methods” section. The MM-PBSA results (Table 2) suggested that
the interaction of 20b with the MAGL binding cavity was more
stable by 8 kcal/mol than its interaction with FAAH and this
energy difference was mainly determined by the lack of strong
electrostatic interactions into the FAAH-binding site.
Conclusions
In summary, we designed and synthesised a new class of ter-
phenyl-2-methyloxazol-5(4H)-one derivatives by optimising the
benzylidene-2-methyloxazol-5(4H)-one scaffold, which was
Table 2. MM-PBSA results for compound 20b docked into MAGL and FAAH.
Protein Ele VdW PBsur PB DPBSA
MAGL 12.5 52.2 43.4 5.2 26.5
FAAH 3.2 50.1 40.2 5.3 18.5
DPBSA is the sum of the electrostatic (Ele), van derWaals (VdW), polar (PB) and
non-polar (PBSur) solvation free energy. Data are expressed as kcalmol1.
Figure 5. Minimised average structure of compound 20b docked into FAAH
receptor.
Figure 4. Minimised average structure of compound 20b docked into MAGL
receptor (A) and analysis of 20b-MAGL H-bond interactions (B). The plot shows
the distance analysis for the two H-bonds (i.e. HB1 and HB2).
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previously identified as a suitable moiety able to efficiently inter-
act with the MAGL-binding site. The reported structural optimisa-
tion led to the identification of compound 20b, which displayed a
high MAGL-inhibition activity with an IC50 value of 348 nM
together with a very good MAGL/FAAH selectivity ratio. Moreover,
the biochemical experiments confirmed the reversible properties
of this compound and, finally, cell-based assays showed promising
cell growth inhibitory activities in the OVCAR-3 and CAOV3 cell
lines which overexpress MAGL. Since the in vivo possible applica-
tion of reversible MAGL inhibitors has only recently been explored,
mainly due to the deficiency of known compounds possessing effi-
cient reversible inhibitory activities, the present findings constitute
an interesting extension to the knowledge of the MAGL inhibition.
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